What is the role of buprenorphine/naloxone (Zubsolv) in the maintenance treatment of opioid abuse?

Updated: Jun 21, 2018
  • Author: David W Dixon, DO; Chief Editor: Glen L Xiong, MD  more...
  • Print

The FDA approved buprenorphine/naloxone (Zubsolv) sublingual tablets in July 2013 for the maintenance treatment of opioid dependence. The new formulation has high bioavailability, a fast dissolve time, a small tablet size, and a menthol flavor to encourage patient adherence with treatment. [40]  Zubsolv’s indication was expanded to include induction dosing for patients dependent on short-acting opioids (eg, heroin) in August 2015. For patients dependent on long-acting opioids (eg, methadone), buprenorphine monotherapy is recommended for induction.

In June 2014, the FDA approved a buccal form of buprenorphine/naloxone (Bunavail) for opioid dependence maintenance therapy. Approval was based on a phase III, 12-week, clinical trial of 249 patients that were converted to the buccal film from the sublingual tablet (Suboxone). The film was shown to be safe and effective with less constipation than with Suboxone. [41]  Suboxone sublingual tablets have been replaced on the market with a Suboxone sublingual film.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!